Literature DB >> 8946301

Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration.

M Schwartz1, M Belkin, E Yoles, A Solomon.   

Abstract

PURPOSE: This article presents the rationale and an experimental strategy for the development of new treatment modalities for glaucomatous neuropathy. Accumulating evidence suggests that regardless of the primary trigger of the retinal and optic nerve damage in glaucoma, the disease will continue to progress even when the cause is removed. The resulting damage can be mimicked by the progression of damage secondary to an acute partial crush injury at the optic nerve head. Such secondary damage includes degeneration of the directly injured optic nerve fibers culminating in death of their cell bodies, as well as degeneration of nerve fibers that escaped acute injury but nevertheless deteriorate as a result of their exposure to injury-induced mediators of secondary degeneration released by the directly affected neurons.
CONCLUSION: We therefore propose that substances found to be effective in rescuing fibers from secondary degeneration and in increasing the survival rate or prolonging survival of retinal ganglion cells in the partially lesioned optic nerve may be useful for the treatment of glaucoma. The new approach does not replace hypotensive therapy, but addresses the glaucoma-induced damage by promoting nerve protection and neuroregeneration.

Entities:  

Mesh:

Year:  1996        PMID: 8946301

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  20 in total

Review 1.  Nitric-oxide synthase and neurodegeneration/neuroprotection.

Authors:  P L Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

Review 2.  Ganglion cell death in glaucoma: what do we really know?

Authors:  N N Osborne; J P Wood; G Chidlow; J H Bae; J Melena; M S Nash
Journal:  Br J Ophthalmol       Date:  1999-08       Impact factor: 4.638

Review 3.  [Neuroprotective approaches].

Authors:  S Thaler; C Haritoglou; F Schuettauf
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

4.  Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies.

Authors:  J Fisher; H Levkovitch-Verbin; H Schori; E Yoles; O Butovsky; J F Kaye; A Ben-Nun; M Schwartz
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

Review 5.  Pharmacotherapy of glaucoma.

Authors:  Doreen Schmidl; Leopold Schmetterer; Gerhard Garhöfer; Alina Popa-Cherecheanu
Journal:  J Ocul Pharmacol Ther       Date:  2015-01-14       Impact factor: 2.671

6.  T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure.

Authors:  Sharon Bakalash; Gil Ben-Shlomo; Gil Ben Shlomo; Eyal Aloni; Iftach Shaked; Larry Wheeler; Ron Ofri; Michal Schwartz
Journal:  J Mol Med (Berl)       Date:  2005-08-12       Impact factor: 4.599

Review 7.  The retina as a window to the brain-from eye research to CNS disorders.

Authors:  Anat London; Inbal Benhar; Michal Schwartz
Journal:  Nat Rev Neurol       Date:  2012-11-20       Impact factor: 42.937

Review 8.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  Neuroprotection for treatment of glaucoma in adults.

Authors:  Dayse F Sena; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 10.  Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension.

Authors:  Risto S Cvetkovic; Caroline M Perry
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.